Stada Pharmaceuticals Australia Pty Ltd

What Stada Pharmaceuticals Australia Pty Ltd does

STADA Pharmaceuticals Australia Pty Ltd is a specialty pharmaceutical and consumer healthcare company incorporated in 2016 as the Australia and New Zealand subsidiary of Frankfurt-listed STADA Arzneimittel AG. The company operates from Frenchs Forest in Sydney with a lean headcount of 11-50 employees, distributing its products across Australia and New Zealand through pharmacy wholesale channels and a direct Clinical Nurse Advisor Service engaging healthcare professionals. Its core technology is a portfolio of prescription and over-the-counter pharmaceutical products rather than a software or platform architecture: the prescription franchise centers on MOVAPO (apomorphine delivery in Pen, pre-filled syringe, and ampoule formats) and Ongentys (opicapone, a COMT inhibitor) for Parkinson's disease treatment, while the consumer healthcare line comprises three established OTC brands, Cerumol (ear wax removal drops), Eurax (10% crotamiton cream for itch relief), and Duofilm (salicylic acid/lactic acid topical solution for warts, corns, and calluses).

The company makes money primarily through one-time product sales of prescription medications via specialty pharmacy channels and over-the-counter consumer healthcare products via pharmacy and retail distribution. Its go-to-market combines enterprise field sales targeting neurologists, Parkinson's specialists, and general practitioners with a Clinical Nurse Advisor Service that supports patients and prescribers, particularly in advanced Parkinson's care. Customer segmentation spans patients with chronic and serious medical conditions, prescribing healthcare professionals, and consumer healthcare end-buyers purchasing from retail pharmacies.

STADA Australia is currently extending beyond its Parkinson's specialty into adjacent therapeutic areas, explicitly naming Neurology, Insomnia, and Post-Operative Pain Management as expansion targets, and maintains an active business development channel for in-licensing, co-development, and divestment partnerships. All prescription products are regulated through Australia's Therapeutic Goods Administration and New Zealand's Medsafe, and the product portfolio is protected by registered trademarks across each brand. Revenue, headcount trends, and capital structure details beyond parent affiliation are not publicly disclosed.

Name

Stada Pharmaceuticals Australia Pty Ltd

Legal name

STADA Pharmaceuticals Australia Pty Limited

Website

https://stada.com.au

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

STADA Pharmaceuticals Australia is a specialty prescription pharmaceutical and consumer healthcare subsidiary of STADA Arzneimittel AG, selling Parkinson's treatments (MOVAPO, Ongentys) and OTC brands (Cerumol, Eurax, Duofilm) across Australia and New Zealand since 2016.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAA

Primary Care & General Medicine Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Specialty pharmaceuticals
• Parkinson's disease treatment
• Consumer healthcare products
• Prescription medications
• Neurology therapeutics

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Prescription Pharmaceutical Products: Revenue generated from prescription pharmaceutical products for chronic and serious medical conditions, particularly Parkinson's disease treatments including MOVAPO products (Pen, PFS, Ampoule) and Ongentys.
2. Consumer Healthcare Products: Revenue from over-the-counter consumer healthcare products including Cerumol (ear drops), Eurax (itch relief cream), and Duofilm (wart treatment solution).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

STADA Pharmaceuticals Australia is a specialty prescription pharmaceutical and consumer healthcare company that sells Parkinson's disease treatments (MOVAPO Pen/PFS/Ampoule and Ongentys) and consumer healthcare products (Cerumol ear drops, Eurax itch relief cream, and Duofilm wart treatment) across Australia and New Zealand. The company operates a Clinical Nurse Advisor Service that partners with healthcare professionals to support patients and families managing chronic and serious medical conditions.

Product overview

STADA Australia is a speciality prescription pharmaceutical and consumer healthcare company operating in Australia and New Zealand since 2016. The prescription product portfolio centers on Parkinson's disease treatment, featuring the MOVAPO® product line (PEN, PFS, and Ampoule formulations delivering apomorphine) and Ongentys® (a COMT inhibitor). The consumer healthcare division offers three main branded products: Cerumol® ear drops for ear wax removal, Eurax® cream for skin itch relief, and Duofilm® topical solution for warts, corns and calluses. The company operates as part of global STADA Arzneimittel AG, selling products in approximately 120 countries worldwide. The prescription products focus on chronic and serious medical conditions, while consumer health products address common health needs.

Differentiator

Problem solved

Functional benefit

Brands

• Cerumol: Ear drops for softening and removing ear wax, also used to prepare ears before syringing
• Eurax
• Duofilm
• MOVAPO
• Ongentys

Products and services

• MOVAPO PEN Prescription medication delivery device for Parkinson's disease treatment, providing subcutaneous apomorphine administration. For patients with Parkinson's disease.
• MOVAPO PFS Pre-filled syringe formulation of apomorphine for Parkinson's disease treatment. For patients with Parkinson's disease.
• MOVAPO Ampoule Ampoule formulation of apomorphine for Parkinson's disease treatment. For patients with Parkinson's disease.
• Ongentys Prescription medication for Parkinson's disease treatment (opicapone, a COMT inhibitor). For patients with Parkinson's disease.
• Cerumol Ear drops that soften and remove ear wax. Gentle formulation for treating problem earwax or preparing ears before syringing, comes with a dropper with screw-on lid. For consumers in Australia and New Zealand.
• Eurax Eurax 10% Cream provides fast-acting and long-lasting relief from itchy and irritated skin caused by dermatitis, dry eczema, allergic rashes, hives, nettle rashes, chickenpox, insect bites and stings, heat rashes, sunburn and personal itching. For consumers in Australia.
• Duofilm Duofilm topical solution (15 ml) for treatment of warts, corns and calluses on hands and feet for adults and children aged 4+. For consumers in Australia.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Healthcare ProfessionalscoreStrategic or Co-development PartnerSTADA Australia partners with healthcare professionals through its Clinical Nurse Advisor Service to provide high-quality service for patients and families. This partnership supports the delivery of prescription products for chronic and serious medical conditions, particularly Parkinson's disease treatment.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Lundbeck Australia: Australian affiliate of H. Lundbeck, a global specialty CNS pharma company with a strong Parkinson's and neurology portfolio. Highly comparable given direct overlap in specialty Parkinson's and movement-disorder therapeutics in AU.
• Mayne Pharma: Australia-headquartered specialty pharma company with branded Rx and consumer healthcare products. Comparable as a locally based specialty pharma competitor targeting similar HCP and pharmacy channels.
• AbbVie Australia: Specialty pharma affiliate with strong neurology and consumer healthcare exposure. Comparable as a large specialty pharma operator in Australia running both Rx and OTC/HCP service models.
• UCB Australia: Specialty pharma affiliate with a neurology portfolio including Parkinson's-adjacent therapies. Comparable as a mid-to-large specialty CNS player operating in AU/NZ with high-HCP-touch sales.
• Aspen Pharmacare Australia: Australian subsidiary of Aspen Pharmacare, a specialty and consumer pharma group with broad Rx/OTC portfolio in AU. Comparable as a diversified specialty + consumer pharma operator of similar size in Australia.
• Boehringer Ingelheim Australia: Specialty pharma affiliate with Parkinson's and neurology products and patient services. Comparable in therapeutic focus, Australian scale, and field-sales-led commercialization model.

Emerging players

• Emerge Health: Australian specialty pharma company focused on neurology, rare disease and specialty therapeutics. Comparable as a smaller specialty player in overlapping CNS and chronic disease categories.

Broad incumbents

• Roche Products Australia: Australian affiliate of Roche, a top-tier global pharma with neurology and Parkinson's-adjacent franchises. Comparable as a broad incumbent overlapping in specialty neurology and chronic disease.
• Novartis Australia: Australian affiliate of Novartis, a top-tier global pharma with neurology, Parkinson's and consumer health exposure. Comparable as a broad incumbent competing across specialty Rx and consumer OTC.
• Bayer Australia & New Zealand: ANZ affiliate of Bayer, combining specialty pharma and large OTC consumer health brands. Comparable as a broad incumbent that combines prescription specialty with established consumer healthcare brands in AU/NZ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stada-australia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stada Pharmaceuticals Australia Pty Ltd